1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Anxo Pharmaceutical Co., Ltd.

Anxo Pharmaceutical Co., Ltd.

6677.TWO
Anxo Pharmaceutical Co., Ltd.TW flagTaipei Exchange
17.50
TWD
-0.40
- -
979.65MMarket Cap
Anxo Pharmaceutical Co., Ltd.
6677.TWO
(Taipei Exchange)

Recent

price

17.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
22.95
18.74
14.66
15.45
18.26
18.87
17.39
16.5
17.99
18.49
16.07
- -
Revenue per Share
- -
0.94
-0.71
-0.45
-0.63
0.62
0.52
0.63
0.39
-0.26
0.43
-1.03
- -
Basic EPS, GAAP
- -
-1.22
-8.39
-8.18
-0.6
-0.58
0.76
0.88
0.89
1.13
-1.19
0.92
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
0.23
- -
- -
- -
0.4
- -
Dividend per Share
- -
9.26
5.78
8.46
8.11
9.6
10.03
10.07
10.37
10.45
11.81
9.34
- -
Book Value per Share
- -
19.87
15.04
11
12.82
13.66
13.65
15.45
15.84
16.36
22.88
19.61
- -
Tangible Book Value per Share
- -
28
34
44
46
47
47
50
50
48
51
56
- -
Basic Weighted Avg Shares
- -
643
631
642
705
850
878
866
824
866
940
895
843
Sales/Revenue/Turnover
- -
4.74
-3.42
-3.26
-3.13
6.24
5.17
6.6
4.84
0.72
5.65
-6.3
-5.09
Operating Margin (%)
- -
33
40
51
72
75
86
81
74
74
75
77
76
Depreciation Expense
- -
26
-24
-20
-29
29
24
31
19
-13
22
-57
-34
Net Income, GAAP
- -
36
- -
- -
- -
24.42
25.96
21.07
18.85
- -
20.38
- -
- -
Effective Tax Rate (%)
- -
4.1
-3.78
-3.07
-4.11
3.37
2.75
3.63
2.33
-1.45
2.33
-6.39
-4.05
Profit Margin (%)
-203
334
87
-51
96
97
114
239
232
216
492
376
308
Working Capital
357
446
545
679
729
660
670
625
594
562
500
449
395
LT Debt
205
653
618
592
670
703
689
811
832
830
1,203
1,139
1,108
Total Equity
- -
1.99
- -
- -
- -
2.51
2.05
2.7
1.89
- -
2.27
- -
- -
Return on Invested Capital (%)
- -
3.97
- -
- -
- -
2.76
2.59
2.37
1.94
- -
1.82
- -
- -
Return on Capital (%)
- -
- -
-10.5
-6.97
-7.82
7.02
5.28
6.48
3.77
-2.46
3.96
-10.21
-6.52
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.89%
7.84%
-2.74%
Free Cash Flow
-73.3%
-92%
-88.45%
Net Income, GAAP
-103.52%
-176.03%
-40.34%
Sales/Revenue/Turnover
3.23%
-0.36%
-5.81%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
940
2024
- -
- -
- -
- -
895
2025
- -
- -
- -
- -
843

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.43
2024
- -
- -
- -
- -
-1.03
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
0.4
2025
- -
- -
- -
- -
- -
Similar Companies
Veerhealth Care Limited (VEERHEALTH.BO)
Wai Yuen Tong Medicine Holdings Limited (0897.HK)
OMID Holdings, Inc. (OMID)
Columbia Care Inc. (CCHW.NE)
Emcure Pharmaceuticals Ltd. (EMCURE.NS)
Sudeep Pharma Ltd. (SUDEEPPHRM.NS)
Business
Anxo Pharmaceutical Co., Ltd. (6677.TWO) develops, manufactures, and markets specialty generic prescription and over-the-counter (OTC) pharmaceutical products targeting therapeutic areas including cardiovascular and metabolism, central nervous system (CNS), diabetic, gastroenterology, respiratory, anti-infection, dermatology, ophthalmology/otology, nephrology, urology, and orthopedics; offerings encompass oral medications, injections, dermatology/external use preparations, and OTC drugs, with a focus on advanced dosage forms such as extended-release, controlled-release, and specialty generics that represent many first-to-market approvals in Taiwan. The company, founded in 2003 and headquartered in Taipei, Taiwan, with an R&D center in Hsinchu, operates primarily in Taiwan while pursuing international partnerships across Asia, Europe, and America through sales authorization, contract manufacturing (CMO), contract development (CDMO), technology transfer, and co-development models. Anxo leverages proprietary technology platforms for specialty dosage forms, formulation/process development, and analytical methods to enhance patient compliance, reduce side effects, and support 505(b)(2) products. In recent developments, Anxo partnered with Sunny Pharmtech Inc. in 2024 to co-develop high-margin cardiovascular drugs, including a rare disease softgel formulation (TFM-SC) targeting the U.S. market with planned regulatory filing by 2027, building on prior pulmonary fibrosis collaboration; the company also expanded ties with a U.S. entity for additional products like TMN-T (oncology) and MSL-T (ulcerative colitis). Further, Anxo entered a strategic collaboration with EUSOL Biotech Co., Ltd. to develop novel oral anticoagulants and niche generic drugs, capitalizing on post-patent opportunities in Taiwan; in September 2025, it filed a U.S. FDA Phase I IND for schizophrenia treatment AX251. These initiatives underscore Anxo's shift toward global expansion, CMO/CDMO growth, and innovative pipelines amid evolving international pharmaceutical dynamics.